<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Vaxart Inc (NASDAQ: VXRT) has granted Altesa Biosciences Inc an exclusive worldwide license to develop and commercialize Vaxart’s patented formulation of the capsid-binding Vapendavir, a clinical-stage broad-spectrum antiviral. Under the terms of the agreement, Vaxart is eligible to receive up to $130 million in milestone payments and tiered royalties ranging from the low-single to low-double digits on product sales for multiple indications.
...read full article on Benzinga
